Mintz Represents Naurex Inc.
The Situation
Mintz represented Naurex Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging disorders of the central nervous system, in its merger with leading global pharmaceutical company, Allergan PLC.
The Approach
Under the agreement, Allergan acquired Naurex for a $560 million upfront payment net of cash acquired, $460 million of which was payable upon the closing of the acquisition and $100 million of which was payable by January of 2016 as well as potential R&D success-based and sales-threshold milestone payments. Michael L. Fantozzi, Managing Member of Mintz’s Boston office and Division Head for the firm’s Corporate & Securities Practice, and Ran Zioni a Member of the Life Sciences Practice, represented Naurex in this transaction.
The Outcome
As part of the transaction, Naurex’s platform was spun out into a new company that will enter into a research collaboration with Allergan.
Supporting Professionals
